{
    "clinical_study": {
        "@rank": "152880", 
        "arm_group": [
            {
                "arm_group_label": "ERCC-1 low", 
                "arm_group_type": "Experimental", 
                "description": "modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid  (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly"
            }, 
            {
                "arm_group_label": "ERCC-1 high", 
                "arm_group_type": "Experimental", 
                "description": "FOLFIRI + Cetuximab irinotecan 180 mg/m\u00b2 on day 1, 15 q d29 for 6 cycles folinic acid  (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly"
            }
        ], 
        "brief_summary": {
            "textblock": "This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene\n      expression status suggests better clinical results from historical experience in metastatic\n      colorectal cancer (mCRC). In wild type KRAS mCRC patients treated with either FOLFOX or\n      FOLFIRI in combination with cetuximab the median response rate is approximately 60-65%.\n      Biomarker directed treatment in this study may demonstrate that patients with low ERCC-1\n      treated with FOLFOX and cetuximab, and those with high ERCC-1 treated with FOLFIRI and\n      cetuximab, will improve response rate to 70-75%.  KRAS wild type patients will be treated\n      with 6 cycles of one of the following regimens chosen for optimization based on patient\n      characteristics (primary treatment phase). Patients with ERCC-1 < 1.7 relative gene\n      expression of ERCC-1 over \u00df-actin (ERCC-1 low) will be assigned to treatment with mFOLFOX6\n      in combination with Cetuximab. Patients with ERCC-1 gene expression > 1.7 relative gene\n      expression of ERCC-1 over over \u00df-actin (ERCC-1 high) will be assigned to treatment with\n      FOLFIRI in combination with Cetuximab."
        }, 
        "brief_title": "Biomarker Directed Treatment in Metastatic Colorectal Cancer", 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.1 Inclusion criteria for pre-screening phase:\n\n          -  Untreated advanced metastatic colorectal cancer patients\n\n          -  Adequate tissue to evaluate for genotyping (10 x 10\u00b5m thick formalin fixed paraffin\n             embedded tissue sections and one corresponding HE stained slide or a FFPE tumor\n             block)\n\n        1.2 Inclusion criteria for treatment phase:\n\n        Patients must fulfill all criteria listed below prior to enrolment in the study:\n\n          -  Untreated wild-type KRAS metastatic colorectal cancer\n\n          -  Previous adjuvant therapy must have been completed > 6 months before therapy\n             initiation on this study\n\n          -  Age >18 years\n\n          -  Measureable disease with CT or MRI\n\n          -  ECOG performance status of 0-2\n\n          -  Adequate organ function\n\n               -  Hematologic:\n\n                    -  Absolute neutrophil count > 1,500/\u00b5L\n\n                    -  Hemoglobin >9 mg/dl\n\n                    -  Platelet count >100,000 /\u00b5l\n\n               -  Renal:\n\n                    -  Serum creatinine <1.5 x Upper limit of normal (UPN) or estimated clearance\n                       > 30 ml/min\n\n               -  Hepatic:\n\n                    -  Serum bilirubin < 1.5 mg/dl\n\n        Exclusion Criteria:\n\n          -  Creatinine clearance below 30 ml/min\n\n          -  Patients with a history of other malignancies within 2 years prior to study entry,\n             except for adequately treated carcinoma in situ of the cervix; basal or squamous cell\n             skin cancer; low grade, early stage localized prostate cancer treated surgically with\n             curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with\n             curative intent.\n\n          -  Patients with a history of severe cardiac disease; e.g. NYHA Functional Class III or\n             IV heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias\n             requiring ongoing treatment, or unstable angina.\n\n          -  Other known co-morbidity with the potential to dominate survival\n\n          -  Hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any\n             of the applied drugs\n\n          -  Pregnant or breast feeding women\n\n          -  Any co-existing medical or psychological condition that would preclude participation\n             in the study or compromise ability to give informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703390", 
            "org_study_id": "AGMT_ERCC1", 
            "secondary_id": "2011-003217-41"
        }, 
        "intervention": [
            {
                "arm_group_label": "ERCC-1 high", 
                "intervention_name": "FOLFIRI + Cetuximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ERCC-1 low", 
                "intervention_name": "modifiedFOLFOX6 + Cetuximab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cetuximab"
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "metastatic colorectal cancer", 
            "mCRC", 
            "ERCC-1", 
            "ERCC1", 
            "AGMT"
        ], 
        "lastchanged_date": "October 8, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "state": "Ober\u00f6sterreich", 
                        "zip": "4021"
                    }, 
                    "name": "AKH Linz, Innere Medizin 3, Zentrum f\u00fcr H\u00e4matologie und medizinische Onkologie"
                }, 
                "investigator": {
                    "last_name": "Michael Fridrik, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "august.zabernigg@bkh-kufstein.at", 
                    "last_name": "August Zabernigg, OA Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Kufstein", 
                        "country": "Austria", 
                        "state": "Tirol", 
                        "zip": "6330"
                    }, 
                    "name": "A.\u00f6. Bezirkskrankenhaus Kufstein, Innere Medizin / H\u00e4matologie / Onkologie"
                }, 
                "investigator": {
                    "last_name": "August Zabernigg, OA Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "alois.lang@lkhf.at", 
                    "last_name": "Alois Lang, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Feldkirch", 
                        "country": "Austria", 
                        "state": "Vorarlberg", 
                        "zip": "6807"
                    }, 
                    "name": "LKH Feldkirch, Interne E"
                }, 
                "investigator": {
                    "last_name": "Alois Lang, OA Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bludenz", 
                        "country": "Austria", 
                        "zip": "6700"
                    }, 
                    "name": "LKH Bludenz Innere Medizin"
                }, 
                "investigator": {
                    "last_name": "Othmar Thurnes, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bregenz", 
                        "country": "Austria", 
                        "zip": "6900"
                    }, 
                    "name": "LKH Bregenz"
                }, 
                "investigator": {
                    "last_name": "Franz X Schmid, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dornbirn", 
                        "country": "Austria", 
                        "zip": "6850"
                    }, 
                    "name": "KH Dornbirn, Innere Medizin"
                }, 
                "investigator": {
                    "last_name": "Guntram Winder, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8036"
                    }, 
                    "name": "Universit\u00e4tsklinikum Graz"
                }, 
                "investigator": {
                    "last_name": "Helmuth Samonigg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hohenems", 
                        "country": "Austria", 
                        "zip": "6845"
                    }, 
                    "name": "LKH Hohenems, Interne Intensivmedizin"
                }, 
                "investigator": {
                    "last_name": "G\u00fcnter H\u00f6fle, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "A-4010"
                    }, 
                    "name": "Krankenhaus d. Barmherzigen Schwestern Linz"
                }, 
                "investigator": {
                    "last_name": "Andreas Petzer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "r.greil@salk.at", 
                    "last_name": "Richard Greil, Prof. Dr.", 
                    "phone": "0043/662/4482", 
                    "phone_ext": "2879"
                }, 
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }, 
                    "name": "Universit\u00e4tsklinik f\u00fcr Innere Medizin III mit H\u00e4matologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum"
                }, 
                "investigator": {
                    "last_name": "Richard Greil, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "d.wolkersdorfer@agmt.at", 
            "last_name": "Richard Greil, MD", 
            "phone": "00436628842", 
            "phone_ext": "4109"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treatment response according to Response Evaluation Criteria In Solid Tumors [RECIST]", 
            "measure": "Response", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703390"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To establish the feasibility of conducting a biomarker based trial of ERCC-1, in wt KRAS mCRC patients in the cooperative group setting to assess progression free survival (PFS) and overall survival (OS) intients with biomarker directed treatment", 
                "measure": "Feasibility", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Description of group differences between ERCC-1 low and ERCC-1 high patients with respect to response rate, PFS and OS", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Description of group differences between ERCC-1 low and ERCC-1 high patients with respect to KRAS status", 
                "measure": "Patient characteristics", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Secondary resection rate", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Molecular markers for toxicity", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Analysis of occuring adverse events during the study treatment according to Common Terminology Criteria for Adverse Events (CTCAE)", 
                "measure": "Toxicity", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Arbeitsgemeinschaft medikamentoese Tumortherapie", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Arbeitsgemeinschaft medikamentoese Tumortherapie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}